DEVICE, DRUG EXPORT CERTIFICATE APPLICATION FEES PLANNED BY FDA
This article was originally published in The Gray Sheet
Executive SummaryDEVICE, DRUG EXPORT CERTIFICATE APPLICATION FEES PLANNED BY FDA, according to a compliance policy guide on agency export policy released Sept. 7. FDA says in a same-day Federal Register notice announcing availability of the document that for products such as devices and drugs that fall under its jurisdiction, the agency intends to provide export certification "with the anticipation of achieving full cost recovery by charging the requester a fee based on the actual expenses incurred." The agency says it will carry out export certification services "either itself or by third parties under FDA oversight."
You may also be interested in...
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.
With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.